TY - JOUR
T1 - Impact of the Surveillance Interval on the Survival of Patients Who Undergo Curative Surgery for Gastric Cancer
AU - Park, Chan Hyuk
AU - Park, Jun Chul
AU - Chung, Hyunsoo
AU - Shin, Sung Kwan
AU - Lee, Sang Kil
AU - Cheong, Jae Ho
AU - Hyung, Woo Jin
AU - Lee, Yong Chan
AU - Noh, Sung Hoon
AU - Kim, Choong Bae
N1 - Publisher Copyright:
© 2015, Society of Surgical Oncology.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Background: For patients who undergo gastrectomy for gastric cancer, systematic follow-up evaluation to detect recurrent lesions is recommended, although the benefits of a surveillance program using short-term imaging studies have not been evaluated. Methods: This study reviewed the clinical data of patients who underwent curative surgery for gastric cancer using a prospective database. Patients with recurrence were classified according to surveillance interval as follows: ≤3, 3–6, and 6–12 months. Results: Of the 2785 patients who underwent curative surgery for gastric cancer, 376 (13.5 %) had intraabdominal recurrences, excluding the stomach. Multivariable analysis showed that a short surveillance interval did not increase the post-recurrence survival duration (with 6–12 months as the reference: ≤3 months: hazard ratio [HR] 0.954; 95 % confidence interval [CI] 0.689–1.323; 3–6 months: HR 0.994, 95 % CI 0.743–1.330). In addition, short surveillance intervals did not increase overall survival (with 6–12 months as the reference: ≤3 months: HR 0.969; 95 % CI 0.699–1.342; 3–6 months: HR 0.955; 95 % CI 0.711–1.285). In contrast to the surveillance interval, age, cancer stage, symptoms at recurrence, and recurrence time after gastrectomy were factors associated with both post-recurrence survival and overall survival. Conclusions: Although the detection of recurrence before symptoms helped to prolong both post-recurrence survival and overall survival, shortening the surveillance interval to less than 6 months did not improve either the patient’s post-recurrence survival or overall survival. Hence, it is not recommended that asymptomatic patients undergo surveillance involving imaging studies more often than once a year.
AB - Background: For patients who undergo gastrectomy for gastric cancer, systematic follow-up evaluation to detect recurrent lesions is recommended, although the benefits of a surveillance program using short-term imaging studies have not been evaluated. Methods: This study reviewed the clinical data of patients who underwent curative surgery for gastric cancer using a prospective database. Patients with recurrence were classified according to surveillance interval as follows: ≤3, 3–6, and 6–12 months. Results: Of the 2785 patients who underwent curative surgery for gastric cancer, 376 (13.5 %) had intraabdominal recurrences, excluding the stomach. Multivariable analysis showed that a short surveillance interval did not increase the post-recurrence survival duration (with 6–12 months as the reference: ≤3 months: hazard ratio [HR] 0.954; 95 % confidence interval [CI] 0.689–1.323; 3–6 months: HR 0.994, 95 % CI 0.743–1.330). In addition, short surveillance intervals did not increase overall survival (with 6–12 months as the reference: ≤3 months: HR 0.969; 95 % CI 0.699–1.342; 3–6 months: HR 0.955; 95 % CI 0.711–1.285). In contrast to the surveillance interval, age, cancer stage, symptoms at recurrence, and recurrence time after gastrectomy were factors associated with both post-recurrence survival and overall survival. Conclusions: Although the detection of recurrence before symptoms helped to prolong both post-recurrence survival and overall survival, shortening the surveillance interval to less than 6 months did not improve either the patient’s post-recurrence survival or overall survival. Hence, it is not recommended that asymptomatic patients undergo surveillance involving imaging studies more often than once a year.
UR - http://www.scopus.com/inward/record.url?scp=84958157823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958157823&partnerID=8YFLogxK
U2 - 10.1245/s10434-015-4866-8
DO - 10.1245/s10434-015-4866-8
M3 - Article
C2 - 26424325
AN - SCOPUS:84958157823
SN - 1068-9265
VL - 23
SP - 539
EP - 545
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 2
ER -